Loading…
← CockpitCompetitor Analysis › RUBICON.NS Rubicon Research LimitedOpen in the cockpit ↗

Rubicon Research LimitedRUBICON.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Biotechnology

Indian specialty pharma company developing complex generic and modified-release drug formulations, mainly for the US market.

Momentum leader 89
Mkt cap
$2.94B
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$3.31M
20-day average traded
Fwd P/E
66.6×
forward earnings
ROIC−WACC
+1.2 pp
WACC 18.7%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · INR₹1,658
1D-1.5%
1W-3.8%
1M+11.5%
3M-8.1%
6M+68.5%
YTD+143.6%
1Y+164.4%
ATR %4.2%
Beta0.35
52w lowhigh12.7% off high

What Rubicon Research does

Indian specialty pharma company developing complex generic and modified-release drug formulations, mainly for the US market.

Products and services

  • Complex generic formulations
  • Modified-release/abuse-deterrent drugs
  • Contract development services

Customers

  • US pharmacy/distribution channels
  • Pharma partners (licensing/co-development)

Where it sits in the supply chain

  • Pharmaceuticals
  • Specialty/complex generic drug…
  • US market-focused product filings…

What could go right

  • US generic drug approvals (ANDA pipeline)
  • Complex-generic pricing/less competition

What could go wrong

  • FDA approval/regulatory delay risk
  • US generic price erosion

Moat: narrow (IP / patents, process know-how). Formulation expertise in complex generics creates technical barriers, though competition from larger Indian generic makers is intense.

Headquarters: Navi Mumbai, India · Employees: 1,303

Named competitors

Rubicon Research at a glance

Size Rubicon Research (RUBICON.NS) is an India Health Care company (Biotechnology) with a market value of $2.94B, the 297th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,658 on 18 Nov 2026.

Performance Over six months the shares gained 68.5%, against -3.3% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 37.0% over the last twelve months (peer median +5.3%); the operating margin is 21.1% (peer median -0.7%).

Valuation It trades at 66.6× forward earnings against a peer median of 26.7× (2nd most expensive of 10).

Capital Return on invested capital runs 1.2 points above its cost of capital (18.7% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026RUBICON.NS 168Peer median 96
Six months, rebased to 100: Rubicon Research against the median of its 20 peers (local-currency closes).

Rubicon Research financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹21.0B₹17.5B₹12.7B₹8.48B₹3.91B
Revenue growth—+37%+50%+117%—
Gross profit₹10.6B₹8.17B₹5.82B₹3.51B₹1.03B
EBITDA₹5.00B₹3.95B₹2.48B₹1.53B₹178M
Net income₹3.25B₹2.47B₹1.34B₹910M-₹169M
Free cash flown/a-₹553M₹575M-₹633M-₹1.35B
Capital expendituren/a₹2.29B₹702M₹561M₹445M
Total debt₹5.01B₹3.11B₹4.18B₹4.41B₹3.20B

Quarterly statements and history in the cockpit →

Rubicon Research competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%DNLIDYNTLXADMA2228BAVA9688XERSVIRP028300MBXELVNXNCR688278IOVA300142RUBICON.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Rubicon Research is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×100×200×300×TLXADMABAVAXERSVIRP002007688278600161300142RUBICON.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Rubicon Research is the large dot.

Rubicon Research competitors and peer comparison

Head to head with its named competitors (RUBICON.NS vs SUNPHARMA.NS vs LUPIN.NS vs AMRX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Rubicon Research RUBICON.NS$2.94B+68%+37%21%66.6×n/a
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Lupin LUPIN.NS$9.67B-14%+24%24%21.0×8.8%
Amneal Pharmaceuticals AMRX$7.62B+79%+9%16%19.2×17.2%

How Rubicon Research compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Rubicon Research against its 20 peers (data as of 18 Nov 2026)
MeasureRUBICON.NSPeer medianRank in peer set
1-month return+11.5%-4.6%4th highest of 21
6-month return+68.5%-3.3%5th highest of 21
Distance from 52-week high-12.7%-31.6%4th highest of 21
Revenue growth (TTM)+37.0%+5.3%3rd highest of 17
Operating margin21.1%-0.7%4th highest of 18
Forward P/E66.6×26.7×2nd most expensive of 10
ROIC minus cost of capital+1.2 pp-6.5 pp7th highest of 18
EV / EBITDA55.4×12.8×2nd most expensive of 6
Net debt / EBITDA0.4×1.1×3rd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%66.6×n/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%n/an/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%n/an/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%16.6×-4.3%+27.4%
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%n/an/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%n/an/an/a
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%n/an/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
Xencor XNCRUnited States$2.58B+204%+34%-73%n/an/an/a
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%15.0×-0.6%+36.0%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%348.7×29.5%-3.8%

Questions

Who are Rubicon Research's main competitors?
Named competitors: Sun Pharmaceutical Industries (SUNPHARMA.NS), Lupin (LUPIN.NS), Amneal Pharmaceuticals (AMRX). The cockpit's measured peer set (industry) also includes Denali Therapeutics (DNLI), Dyne Therapeutics (DYN), Telix Pharmaceuticals (TLX.AX), ADMA Biologics (ADMA), XtalPi (2228.HK), Bavarian Nordic A/S (BAVA.CO).
Is Rubicon Research expensive compared with its peers?
On forward p/e it trades at 66.6× against a peer median of 26.7×, 2nd most expensive of 10 in its peer set.
How has Rubicon Research stock performed?
Over six months to 18 Nov 2026 the shares returned +68.5% against -3.3% for the median peer; over one year +164.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.